New Retina Radio:

New Retina Radio Meeting Coverage

New Retina Radio Meeting Coverage

06.09.22

ARVO Meeting Coverage Day 3: CANDELA and ARCHWAY Data

Could an 8-mg dose intensify the therapeutic effect of aflibercept (Eylea, Regeneron) in patients with wet AMD? The phase 2 CANDELA study sought to explore the safety and efficacy of high-dose aflibercept in this patient population. What did David Brown, MD, and his research colleagues observe?  And 96-week data from ARCHWAY are in. Did the complete study, which reached its primary endpoint after 40 weeks, reveal new data that could affect clinical decision-making when it comes to real-world use of the Port Delivery System with Ranibizumab (Susvimo, Genentech)? Hear our interview with Robert Mittra, MD, to find out.  This editorially independent podcast is supported with advertising.

Other Podcast Episodes

08.21.25

ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders

John Kitchens, MD; Krishna Mukkamala, MD

06.12.25

Duke AVS Clips: PVR, DR, Imaging, and MTM

Jason Hsu, MD; Majda Hadziahmetovic, MD; Aleksandra Rachitskaya, MD; Gavin Tan, MD, PhD, FRCSed

06.09.25

Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI

Lejla Vajzovic, MD; Jason Fan, MD; Glen J. Jaffe, MD

06.05.25

Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs

Avni P. Finn, MD, MBA; Lejla Vajzovic, MD, MBA; David Zacks, MD, PhD; Dilraj S. Grewal, MD; Xi Chen, MD, PhD; Yuxi Zheng, MD; Durga Borkar, MD; and Yannek I. Leiderman, MD, PhD

05.29.25

ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

Marion Munk, MD, PhD; and Diana Do, MD

05.22.25

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD

11.07.24

AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD

Jeremiah Brown, MD, MS; and Eric Schneider, MD

Show More